Syros PharmaceuticalsSYRS
Market Cap: $53.1M
About: Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Employees: 68
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
747% more call options, than puts
Call options by funds: $144K | Put options by funds: $17K
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
4.23% less ownership
Funds ownership: 80.48% [Q1] → 76.25% (-4.23%) [Q2]
6% less capital invested
Capital invested by funds: $112M [Q1] → $105M (-$6.81M) [Q2]
7% less funds holding
Funds holding: 75 [Q1] → 70 (-5) [Q2]
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Piper Sandler Edward Tenthoff 35% 1-year accuracy 11 / 31 met price target | 153%upside $5 | Overweight Reiterated | 13 Aug 2024 |
JMP Securities Jason Butler 56% 1-year accuracy 22 / 39 met price target | 102%upside $4 | Market Outperform Maintained | 13 Aug 2024 |
HC Wainwright & Co. Andrew Fein 45% 1-year accuracy 73 / 162 met price target | 203%upside $6 | Buy Maintained | 13 Aug 2024 |
HC Wainwright & Co. Andrew Fein 45% 1-year accuracy 73 / 162 met price target | 658%upside $15 | Buy Reiterated | 1 Aug 2024 |
HC Wainwright & Co. Andrew Fein 45% 1-year accuracy 73 / 162 met price target | 658%upside $15 | Buy Reiterated | 26 Jun 2024 |
Financial journalist opinion
Based on 76 articles about SYRS published over the past 30 days